Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 15.25p 15.00p 15.50p 15.25p 15.25p 15.25p 50,900 07:31:56
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.6 -4.2 - 11.30

Evgen Pharma (EVG) Latest News

More Evgen Pharma News
Evgen Pharma Takeover Rumours

Evgen Pharma (EVG) Share Charts

1 Year Evgen Pharma Chart

1 Year Evgen Pharma Chart

1 Month Evgen Pharma Chart

1 Month Evgen Pharma Chart

Intraday Evgen Pharma Chart

Intraday Evgen Pharma Chart

Evgen Pharma (EVG) Discussions and Chat

Evgen Pharma Forums and Chat

Date Time Title Posts
26/9/201711:31Evgen Pharma: Developing Sulforaphane to treat Stroke, MS and Cancer62
26/6/201707:38Evgen Pharma Plc Investor Presentation-
13/6/201709:45Evgen Pharma Interview-
29/11/201608:27Evgen Pharma (EVG) chief executive Stephen Franklin39
24/8/201615:30EVG39

Add a New Thread

Evgen Pharma (EVG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
12:00:4215.205,000759.75O
11:54:0915.033,128469.98O
10:46:1514.5030,0004,350.00O
09:52:2315.035,429815.71O
09:28:0015.507,3431,138.17O
View all Evgen Pharma trades in real-time

Evgen Pharma (EVG) Top Chat Posts

DateSubject
26/9/2017
09:20
Evgen Pharma Daily Update: Evgen Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 15.25p.
Evgen Pharma has a 4 week average price of 13p and a 12 week average price of 13p.
The 1 year high share price is 30p while the 1 year low share price is currently 13p.
There are currently 74,110,191 shares in issue and the average daily traded volume is 16,981 shares. The market capitalisation of Evgen Pharma is £11,301,804.13.
26/9/2017
11:31
pdt: Another good piece of research on Sulforaphane and breast cancer; Sulforaphane-Induced Cell Cycle Arrest and Senescence are accompanied by DNA Hypomethylation and Changes in microRNA Profile in Breast Cancer Cells hTTp://www.thno.org/v07p3461.htm A bit disappointing that the share price is drifting lower. That will not help the inevitable fund raise. Hopefully, there will be some positive news before they complete that. I have been buying on the way down but now I have probably as many as I want to hold at this stage.
15/2/2017
08:14
timbo003: This week's (unexpected) performance has to be worth an animated gif! I'm not sure what the catalyst is for this recent rise, a patent grant (even in the US) doesn't normally have an effect of this magnitude on the share price.
25/7/2016
18:47
timbo003: Presumably this new article on Proactiveinvestor was the catalyst for the excitement today: http://www.proactiveinvestors.co.uk/companies/news/128572/evgen-pharma-and-the-power-of-plants-for-potential-drug-breakthrough-128572.html It's well written but contains no new news, so it wouldn't surprise me if the share price drifts back down again. I suspect the next significant news will be MRHA approval for the Metastatic breast cancer study
30/10/2011
19:43
call-logger: Subject to the Court sanctioning the Scheme and the satisfaction of certain other outstanding conditions, it is expected that the last day for dealings in Evolution Shares will be 6 December 2011 and the Scheme will become effective on 7 December 2011. If you're selling, the takeover date doesn't really matter to you. The share price is now purely based on the market's view of Investec
08/11/2009
18:17
plast: well if that is the result to the share price, then they can sell some more.
08/1/2008
19:48
msy: No share price movement to the following news? BES could make full bid for Evolution if strategic alliance goes well LISBON (Thomson Financial) - Banco Espirito Santo could make a full bid for the Evolution Group, in which it bought a 9.95 pct stake yesterday, if the strategic alliance between the Portuguese bank and the UK broker goes well, the Daily Telegraph reported, without citing a source. According to the newspaper, BES bought the stake in Evolution to offer international clients access to the London market through the UK-based financial holding's investment arm. If the arrangement works well, BES may make an offer for the whole of the UK business which is worth 260 mln stg, the paper said. Yesterday, BES investment unit BESI said it acquired its 9.95 pct stake for around 26.1 mln stg (about 35.5 mln eur). Evolution might be attractive to a buyer because the volatile earnings from its investment banking business were offset by more steady profits from its asset-management business, gained when it bought Williams de Broe from ING in 2006, the paper added.
11/10/2007
15:50
eastbourne1982: moving very strongly this afternoon and starting to build up some decent momemtum, could be the start of a recovery in the share price
08/10/2007
11:58
eastbourne1982: any ideas what is going on here, pretty much at a 3 - 4 year in terms of share price, all seems very strange as there cannot be a lot wrong with this company, I will continue to hold, may just take a little longer to see £1.30 again !!
28/3/2007
09:08
seagreen: Incredible change around in the shareholders register over the last couple of months with well known value seekers and activist shareholders famous for extracting value or seeking long term growth coming on board with large stakes and there is no way they have come on board because Evolution is the city darling especially after TXO etc Surely it means they think the sum of the parts and the cash must be worth a lot more than the current share price be it as one company or as individual companies...Anyway I have gone long a few to see what happens
20/11/2004
18:55
maut too: Brokers' say (Filed: 20/11/2004) Brokers' updates are compiled by Hargreaves Lansdown. The stockbrokers' views summarised here are their own and not necessarily those of money.telegraph or Hargreaves Lansdown Evolution Hold at 154p, advises Credit Suisse First Boston (153p this week). Recent first-half results from the small investment bank showed strong progress being made, with revenues increasing by 126 per cent on the previous year. This revenue growth has translated into a signi. cant increase in pro. ts as a result of the group's operational gearing. Evolution continues to carve out a positive niche for itself, although the barriers to entry are low. CSFB believes the share price strength is deserved.
Evgen Pharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170926 12:55:58